aniracetam has been researched along with Cognition Disorders in 3 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease." | 2.41 | Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. ( Nakamura, K, 2002) |
| "Aniracetam is a member of the nootropic class of drugs, which have possible cognition enhancing effects." | 2.39 | Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. ( Benfield, P; Lee, CR, 1994) |
| "In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a considerable number of patients with dementia." | 1.38 | Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study. ( Koliaki, CC; Messini, C; Tsolaki, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koliaki, CC | 1 |
| Messini, C | 1 |
| Tsolaki, M | 1 |
| Lee, CR | 1 |
| Benfield, P | 1 |
| Nakamura, K | 1 |
2 reviews available for aniracetam and Cognition Disorders
| Article | Year |
|---|---|
Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.
Topics: Aged; Aging; Animals; Cognition Disorders; Drug Administration Schedule; Drug Tolerance; Humans; Pyr | 1994 |
Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.
Topics: Acetylcholine; Animals; Biogenic Monoamines; Brain; Brain Diseases; Cognition Disorders; Glutamic Ac | 2002 |
1 other study available for aniracetam and Cognition Disorders
| Article | Year |
|---|---|
Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Drug Therap | 2012 |